Russo Giuliano, de Oliveira Lícia, Shankland Alex, Sitoe Tânia
International health and biostatistics department, Instituto de Higiene and Medicina Tropical, Universidade Nova de Lisboa, Rua da Junqueira 100, Lisbon, Portugal.
Global Health. 2014 Sep 25;10:70. doi: 10.1186/s12992-014-0070-z.
On the back of its recent economic development and domestic success in the fight against HIV/AIDS, Brazil is helping the Government of Mozambique to set up a pharmaceutical factory as part of its South-South cooperation programme. Until recently, a consensus existed that pharmaceutical production in Africa was not viable or sustainable. This paper looks into practicalities and evolution of this collaboration to illustrate the characteristics of Brazilian development cooperation in health, with the aim of drawing lessons for the wider debate on aid and local production of pharmaceuticals in Africa.
We show that the project process has been very long and complex, has involved multiple public and private partners, and cost in excess of USD34 million. There have also been setbacks in the process, and although production has already started, it is unclear whether all the project's original objectives will be met.
The Brazil-Mozambique's pharmaceutical factory experience illustrates positives as well as limitations of Brazil's unorthodox approach to health development cooperation, highlighting its contribution to pushing the boundaries of the debate on local production of pharmaceuticals in resource-poor settings.
在近期经济发展以及国内抗击艾滋病毒/艾滋病取得成功的背景下，巴西正协助莫桑比克政府建立一家制药厂，作为其南南合作项目的一部分。直到最近，人们还普遍认为非洲的制药生产不可行或不可持续。本文探讨了这一合作的实际情况和发展历程，以阐明巴西在卫生领域发展合作的特点，旨在为关于非洲援助和药品本地生产的更广泛辩论提供经验教训。
我们表明，该项目过程漫长而复杂，涉及多个公共和私人合作伙伴，成本超过3400万美元。在此过程中也遇到了挫折，尽管生产已经开始，但尚不清楚该项目的所有最初目标是否能够实现。
巴西-莫桑比克制药厂的经验既体现了巴西非传统卫生发展合作方式的积极方面，也凸显了其局限性，突出了其在推动资源匮乏地区药品本地生产辩论边界方面的贡献。
